NAP1L1 and neuroendocrine neoplasm: Deregulation of NAP1L1 expression has been documented for several tumors such as small intestine carcinoid neoplasia [70], neuroendocrine tumors [71], ovarian cancer [72] and hepatoblastomas [73].